{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35","upperLimit":"71","value":"55"},{"groupId":"OG001","lowerLimit":"36","upperLimit":"84","value":"65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Time from randomization to the time of first indication of local failure or metastases. Estimated non-parametrically using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.\n\nPatients underwent induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).\n\n(AT-101 Arm) Days #1-3: Patients received AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy.\n\nAT-101: Patients received AT-101 40 mg orally two times a day.\n\nCisplatin: Cisplatin 100 mg/m2\n\nCarboplatin: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg","id":"OG000","title":"Platinum/Docetaxal + AT-101"},{"description":"Patients underwent induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).\n\nDay #23 (+/- 3 days): Patients underwent a direct laryngoscopy (DL) with biopsy. Patients also underwent a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies.\n\nDocetaxel: Docetaxel (Taxotere) 75 mg/m2\n\nCisplatin: Cisplatin 100 mg/m2\n\nCarboplatin: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg","id":"OG001","title":"Active Comparator Arm"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 years after randomization","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}